PKCδ impaired vessel formation and angiogenic factor expression in diabetic ischemic limbs

Diabetes

Volumn 62, Issue 8, 2013, Pages 2948-2957

  Lizotte, Farah ^a   Paré, Martin ^a   Denhez, Benoit ^a   Leitges, Michael ^b   Guay, Andréanne ^a   Geraldes, Pedro ^a  

^a Centre Hospitalier Universitaire de Sherbrooke   (Canada)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE C DELTA; PROTEIN TYROSINE PHOSPHATASE SHP 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; PLATELET DERIVED GROWTH FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD FLOW; BLOOD VESSEL REACTIVITY; CAPILLARY DENSITY; CONTROLLED STUDY; DIABETES MELLITUS; HYPOXIA; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPERFUSION; SIGNAL TRANSDUCTION; TISSUE NECROSIS; UPREGULATION; ANIMAL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HINDLIMB; ISCHEMIA; KNOCKOUT MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHOSPHORYLATION; VASCULARIZATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; HINDLIMB; ISCHEMIA; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE C-DELTA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REPERFUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84891703809     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1432     Document Type: Article

References (50)

1. Gregg EW, Gu Q, Cheng YJ, Narayan KM, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007;147: 149-155
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
4. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008;88:1254-1264
5. Chou E, Suzuma I, Way KJ, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: A possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002;105:373-379
6. Takeshita S, Rossow ST, Kearney M, et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995;147:1649-1660
7. Shyu KG, Manor O, Magner M, Yancopoulos GD, Isner JM. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998;98:2081-2087
8. Li H, Fu X, Zhang L, Huang Q, Wu Z, Sun T. Research of PDGF-BB gel on the wound healing of diabetic rats and its pharmacodynamics. J Surg Res 2008;145:41-48
9. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-2018
10. Vale PR, Losordo DW, Milliken CE, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000;102: 965-974
11. Margolis DJ, Bartus C, Hoffstad O, Malay S, Berlin JA. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Repair Regen 2005;13:531-536
12. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 2003;10:285-291
13. Roguin A, Nitecki S, Rubinstein I, et al. Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model. Cardiovasc Diabetol 2003;2:18
14. Rajagopalan S, Mohler ER 3rd, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase 2 randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933-1938
15. Molin D, Post MJ. Therapeutic angiogenesis in the heart: protect and serve. Curr Opin Pharmacol 2007;7:158-163
16. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395
17. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda) 2009;24:97-106
18. Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995;270:12607-12613
19. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999;154:355-363
20. Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001;107:1083-1092
21. Gao Z, Sasaoka T, Fujimori T, et al. Deletion of the PDGFR-beta gene affects key fibroblast functions important for wound healing. J Biol Chem 2005;280:9375-9389
22. Tanii M, Yonemitsu Y, Fujii T, et al. Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors.Circ Res 2006;98:55-62
23. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKCdelta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med 2009;15:1298-1306
24. Newton AC. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J 2003;370:361-371
25. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487
26. Huang Q, Yuan Y. Interaction of PKC and NOS in signal transduction of microvascular hyperpermeability. Am J Physiol 1997;273:H2442-H2451
27. Park JY, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose: An effect of protein kinase C activation. Diabetes 2000;49:1239-1248
28. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497-1503
29. Pomero F, Allione A, Beltramo E, et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia 2003;46:416-419
30. Haller H, Baur E, Quass P, et al. High glucose concentrations and protein kinase C isoforms in vascular smooth muscle cells. Kidney Int 1995;47:1057-1067
31. Igarashi M, Wakasaki H, Takahara N, et al. Glucose or diabetes activates p38 mitogen-Activated protein kinase via different pathways. J Clin Invest 1999;103:185-195
32. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-2588
33. Yokota T, Ma RC, Park JY, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003;52:838-845
34. Bowling N, Walsh RA, Song G, et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 1999;99:384-391
35. Leitges M, Mayr M, Braun U, et al. Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J Clin Invest 2001;108:1505-1512
36. Sun F, Zhou B, Lin X, Duan L. Proteomic analysis identifies nuclear protein effectors in PKC-delta signaling under high glucose-induced apoptosis in human umbilical vein endothelial cells. Mol Med Rep 2011;4:865-872
37. Ryer EJ, Sakakibara K, Wang C, et al. Protein kinase C delta induces apoptosis of vascular smooth muscle cells through induction of the tumor suppressor p53 by both p38-dependent and p38-independent mechanisms. J Biol Chem 2005;280:35310-35317
38. Kato K, Yamanouchi D, Esbona K, et al. Caspase-mediated protein kinase C-delta cleavage is necessary for apoptosis of vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2009;297:H2253-H2261
39. Bright R, Steinberg GK, Mochly-Rosen D. DeltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo. Brain Res 2007;1144:146-155
40. Tchaikovski V, Olieslagers S, Böhmer FD, Waltenberger J. Diabetes mellitus activates signal transduction pathways resulting in vascular endothelial growth factor resistance of human monocytes. Circulation 2009;120: 150-159
41. Sarkar K, Fox-Talbot K, Steenbergen C, Bosch-Marcé M, Semenza GL. Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci U S A 2009;106:18769-18774
42. Chowdhury AK, Watkins T, Parinandi NL, et al. Src-mediated tyrosine phosphorylation of p47phox in hyperoxia-induced activation of NADPH oxidase and generation of reactive oxygen species in lung endothelial cells. J Biol Chem 2005;280:20700-20711
43. De Falco E, Porcelli D, Torella AR, et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004;104:3472-3482
44. Marrotte EJ, Chen DD, Hakim JS, Chen AF. Manganese superoxide dismutase expression in endothelial progenitor cells accelerates wound healing in diabetic mice. J Clin Invest 2010;120:4207-4219
45. Kusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial. Hum Gene Ther 2006;17:683-691
46. Won KJ, Lee HM, Lee CK, et al. Protein tyrosine phosphatase SHP-2 is positively involved in platelet-derived growth factor-signaling in vascular neointima formation via the reactive oxygen species-related pathway. J Pharmacol Sci 2011;115:164-175
47. Chang Y, Zhuang D, Zhang C, Hassid A. Increase of PTP levels in vascular injury and in cultured aortic smooth muscle cells treated with specific growth factors. Am J Physiol Heart Circ Physiol 2004;287:H2201-H2208
48. Guo DQ, Wu LW, Dunbar JD, et al. Tumor necrosis factor employs a proteintyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 2000; 275:11216-11221
49. Liu SH, Herng Sheu WH, Lee MR, et al. Advanced glycation end product N(ε) -carboxymethyllysine induces endothelial cell injury: the involvement of SHP-1-regulated VEGFR-2 dephosphorylation. J Pathol 12 March 2013 [Epub ahead of print]
50. Sugano M, Tsuchida K, Maeda T, Makino N. SiRNA targeting SHP-1 accelerates angiogenesis in a rat model of hindlimb ischemia. Atherosclerosis 2007;191:33-39